Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Cytokine sensitivity screening highlights BMP4 pathway signaling as a therapeutic opportunity in ER+ breast cancer.

Shee K, Jiang A, Varn FS, Liu S, Traphagen NA, Owens P, Ma CX, Hoog J, Cheng C, Golub TR, Straussman R, Miller TW.

FASEB J. 2019 Feb;33(2):1644-1657. doi: 10.1096/fj.201801241R. Epub 2018 Aug 30.

PMID:
30161001
2.

Identification of a unique Staphylococcus aureus ribosomal signature in severe atopic dermatitis.

Brandwein M, Fuks G, Israel A, Nejman D, Straussman R, Hodak E, Harari M, Steinberg D, Bentwich Z, Shental N, Meshner S.

Br J Dermatol. 2018 Nov;179(5):1222-1224. doi: 10.1111/bjd.16936. Epub 2018 Sep 23. No abstract available.

PMID:
29962038
3.

Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.

Shee K, Yang W, Hinds JW, Hampsch RA, Varn FS, Traphagen NA, Patel K, Cheng C, Jenkins NP, Kettenbach AN, Demidenko E, Owens P, Faber AC, Golub TR, Straussman R, Miller TW.

J Exp Med. 2018 Mar 5;215(3):895-910. doi: 10.1084/jem.20171818. Epub 2018 Feb 7.

4.

Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents.

Geller LT, Straussman R.

Mol Cell Oncol. 2017 Dec 11;5(1):e1405139. doi: 10.1080/23723556.2017.1405139. eCollection 2018.

5.

Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine.

Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R.

Science. 2017 Sep 15;357(6356):1156-1160. doi: 10.1126/science.aah5043.

6.

Temporal Stability of the Healthy Human Skin Microbiome Following Dead Sea Climatotherapy.

Brandwein M, Fuks G, Israel A, Al-Ashhab A, Nejman D, Straussman R, Hodak E, Harari M, Steinberg D, Bentwich Z, Shental N, Meshner S.

Acta Derm Venereol. 2018 Feb 7;98(2):256-261. doi: 10.2340/00015555-2769.

7.

Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade.

Lotem M, Merims S, Frank S, Hamburger T, Nissan A, Kadouri L, Cohen J, Straussman R, Eisenberg G, Frankenburg S, Carmon E, Alaiyan B, Shneibaum S, Ozge Ayyildiz Z, Isbilen M, Mert Senses K, Ron I, Steinberg H, Smith Y, Shiloni E, Gure AO, Peretz T.

J Immunol Res. 2016;2016:8121985. doi: 10.1155/2016/8121985. Epub 2016 May 18.

8.

A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.

Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, Tamayo P, Garraway LA.

Cancer Discov. 2014 Jul;4(7):816-27. doi: 10.1158/2159-8290.CD-13-0424. Epub 2014 Apr 25.

9.

Molecular rules governing de novo methylation in cancer.

Nejman D, Straussman R, Steinfeld I, Ruvolo M, Roberts D, Yakhini Z, Cedar H.

Cancer Res. 2014 Mar 1;74(5):1475-83. doi: 10.1158/0008-5472.CAN-13-3042. Epub 2014 Jan 22.

10.

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.

Lohr JG, Stojanov P, Carter SL, Cruz-Gordillo P, Lawrence MS, Auclair D, Sougnez C, Knoechel B, Gould J, Saksena G, Cibulskis K, McKenna A, Chapman MA, Straussman R, Levy J, Perkins LM, Keats JJ, Schumacher SE, Rosenberg M; Multiple Myeloma Research Consortium, Getz G, Golub TR.

Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.

11.

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR.

Nature. 2012 Jul 26;487(7408):500-4. doi: 10.1038/nature11183.

12.

Genome-wide de novo methylation in epithelial ovarian cancer.

Michaelson-Cohen R, Keshet I, Straussman R, Hecht M, Cedar H, Beller U.

Int J Gynecol Cancer. 2011 Feb;21(2):269-79. doi: 10.1097/IGC.0b013e31820e5cda.

PMID:
21270610
13.

Developmental programming of CpG island methylation profiles in the human genome.

Straussman R, Nejman D, Roberts D, Steinfeld I, Blum B, Benvenisty N, Simon I, Yakhini Z, Cedar H.

Nat Struct Mol Biol. 2009 May;16(5):564-71. doi: 10.1038/nsmb.1594. Epub 2009 Apr 19.

PMID:
19377480
14.

MHC-IIB filament assembly and cellular localization are governed by the rod net charge.

Rosenberg M, Straussman R, Ben-Ya'acov A, Ronen D, Ravid S.

PLoS One. 2008 Jan 30;3(1):e1496. doi: 10.1371/journal.pone.0001496.

15.

Kinking the coiled coil--negatively charged residues at the coiled-coil interface.

Straussman R, Ben-Ya'acov A, Woolfson DN, Ravid S.

J Mol Biol. 2007 Mar 2;366(4):1232-42. Epub 2006 Dec 2.

PMID:
17207815
16.

Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer.

Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE, Bergman Y, Simon I, Cedar H.

Nat Genet. 2007 Feb;39(2):232-6. Epub 2006 Dec 31.

PMID:
17200670
17.

Skip residues and charge interactions in myosin II coiled-coils: implications for molecular packing.

Straussman R, Squire JM, Ben-Ya'acov A, Ravid S.

J Mol Biol. 2005 Oct 28;353(3):613-28. Epub 2005 Aug 24.

PMID:
16181641
18.

Supplemental Content

Loading ...
Support Center